Previous close | 281.90 |
Open | 282.60 |
Bid | 273.80 x 0 |
Ask | 285.60 x 0 |
Day's range | 270.00 - 284.16 |
52-week range | 197.90 - 301.80 |
Volume | |
Avg. volume | 240,871 |
Market cap | 101.192B |
Beta (5Y monthly) | 0.23 |
PE ratio (TTM) | 28.75 |
EPS (TTM) | 9.73 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Tuesday, 14 May 2024 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.